JAN 18, 2016 8:00 AM PST

Scientists Uncover New Cancer Map In Cell-Free DNA

WRITTEN BY: Xuan Pham
When cells die, their genetic contents are released into bodily fluids through a process known as autolysis. In the recent past, scientists have exploited the presence of cell-free DNA in the blood to detect fetal DNA or tumor DNA. A recent study goes even further to predict the origin of the cell-free DNA at the cellular level. This has implications for broadening the scope of detection for many health conditions, including metastatic cancer whose origins are sometimes unknown.
 
New blood test reveals DNA fragment footprints

Traditional testing of cell-free DNA relies on comparing the DNA sequence between the patient’s healthy cells versus another DNA source. This source may be from a fetus, a tumor, or from a transplanted organ. However, these sequence-specific tests are limited, especially when no sequence variations are found.
 
Instead of relying on sequence variations, the new method relies on the fragmentation patterns of the cell-free DNA.
 
In normal cells, DNA is wrapped around protein structures called the nucleosomes, similar to how thread is wrapped around a spool. The spacing of the nucleosomes is unique to different cell types. As cells die, enzymes cut up free-floating DNA, specifically at sections that are not protected by the nucleosomes.
 
And because the pattern of nucleosome packaging is unique, so too are the fragmentation patterns of the cell-free DNA. This brilliant insight was discovered by Matthew W. Snyder, a graduate student in the laboratory of Dr. Jay Shendure, University of Washington professor of genome sciences and a Howard Hughes Medical Institute investigator.
 
Through deep sequencing of the cell-free DNA in blood, the researchers constructed maps of the nucleosome positions in the human genome. They essentially built an “address book” for the nucleosomes, from which they then used to trace the origins of various cell types.
 
In healthy individuals, they found that the cell-free DNA had nucleosome patterns that correlated with normal blood cells. In cancer patients, however, the researchers found totally different nucleosome footprints in the cell-free DNA. By matching the nucleosome pattern in the patient’s blood to the nucleosome map, the scientists could identify the anatomical source of where the tumor originated.
 
"This could be particularly relevant in the 5 percent of metastatic cancers whose original source is unknown," Shendure said.
 
Because the new test doesn’t rely on sequence mismatches from different cells in the body, it can theoretically be applied to a broad range of health conditions that can’t be detected by traditional liquid biopsies. Heart attacks, strokes, and autoimmune diseases, for example, kill off certain cells and releases cell-free DNA with telltale nucleosome footprints. Knowing this can inform physicians on diagnosis and subsequent treatments. 
 

Additional source: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 18, 2019
Clinical & Molecular DX
OCT 18, 2019
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays in oncology testing, Thermo Fisher Scientific with AcroMetrix control products provides innov...
NOV 05, 2019
Clinical & Molecular DX
NOV 05, 2019
Meningitis and Encephalitis: Testing & Diagnosis Strategies for Effective Treatment
Meningitis is an inflammation of the membranes surrounding the brain (meninges) and spinal cord. Encephalitis, on the other hand, refers to inflammation of...
NOV 20, 2019
Clinical & Molecular DX
NOV 20, 2019
New diagnostic technology seeks out cancer DNA in blood
For many cancers, early detection has a tremendous impact on patient outcomes. Yet, sadly, many of the most common malignancies, like those of the stomach,...
JAN 08, 2020
Clinical & Molecular DX
JAN 08, 2020
MicroRNA emerges as a biomarker for migraines
Intense, debilitating pain that can last for days. Nausea, numbness and sensitivity to light. For people who experience migraines, it’s frustrating t...
JAN 28, 2020
Clinical & Molecular DX
JAN 28, 2020
Protein complex discovered as first biomarker of PTSD
  Researchers at the Centre for Addiction and Mental Health (CAMH) and the Canadian Institutes of Health Research (CIHR) have identified a potential d...
FEB 06, 2020
Clinical & Molecular DX
FEB 06, 2020
Concussion detector could pick up concussions in athletes, right from the sidelines
Concussions are brain traumas caused by a blow to the head or a whiplash injury. The risk of concussions are greatly heightened in athletes playing high co...
Loading Comments...